Amgen stock (US0311621009): obesity deal and recent approvals keep pipeline in focus

Amgen has highlighted its obesity drug candidate MariTide, advanced a key oncology acquisition and secured fresh regulatory approvals, keeping its late?stage pipeline and US market exposure in focus for investors.

Amgen is back in the spotlight after recent pipeline and regulatory developments, including progress for its obesity candidate MariTide, an oncology acquisition and new product approvals that underline the biotech group’s focus on high?value specialty drugs, according to company disclosures and regulatory filings in early 2025 and late 2024 from Amgen and US authorities.

As of: 05/18/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Amgen Inc.
• Sector/industry: Biotechnology, pharmaceuticals
• Headquarters/country: Thousand Oaks, California, United States
• Core markets: United States, Europe, Japan and other international markets
• Key revenue drivers: Oncology, cardiovascular and immunology therapies, biosimilars
• Home exchange/listing venue: Nasdaq (ticker: AMGN)
• Trading currency: US dollar (USD)

Amgen: core business model

Amgen is one of the largest independent biopharmaceutical companies worldwide, focused on discovering, developing and commercializing human therapeutics in areas such as oncology, cardiology, inflammation and nephrology. The group’s strategy centers on biologic medicines and, increasingly, on biosimilars to expand its footprint in both specialty and cost?sensitive markets. The company emphasizes large patient populations and serious diseases where targeted therapies can command premium pricing while adding clear clinical benefit, which has helped support substantial cash flows and a steady presence in major US healthcare indices.

The business model combines in?house research and development with selective acquisitions and licensing deals to extend the pipeline. Amgen has historically used its balance sheet to acquire late?stage or commercial assets that can integrate into its global sales infrastructure. This approach was visible in its move to expand in oncology and immunology over recent years, where buying or partnering for assets rather than developing everything internally allowed the company to adjust its portfolio to changing scientific and competitive dynamics in the US and abroad.

A key feature of Amgen’s model is its focus on complex biologic manufacturing capabilities. These capabilities underpin both branded biologics such as Prolia and Repatha and a growing biosimilars portfolio, giving the company a technical and regulatory moat. The firm runs large manufacturing sites in the US and internationally, enabling scaled production for chronic therapies. This capital?intensive setup can create barriers to entry but also requires disciplined portfolio management to keep utilization high as older products face biosimilar competition from rivals.

Main revenue and product drivers for Amgen

Amgen’s revenue base is diversified across several key products, with bone health therapy Prolia and osteoporosis drug Xgeva among the largest contributors in recent years. Cardiovascular drug Repatha, which targets PCSK9 to lower LDL cholesterol, has also become a more meaningful driver as payer coverage expanded in the US, though pricing dynamics remain an important variable for long?term growth. Immunology medicines such as Enbrel, Otezla and Tezspire contribute additional scale, especially in the US market, even as some mature brands face competitive pressures.

Oncology has been a strategic priority. Amgen markets cancer therapeutics such as Kyprolis and Blincyto, while also producing supportive?care agents like Neulasta and Neupogen biosimilars. The acquisition of oncology?focused assets in recent years was intended to deepen this portfolio and to provide additional growth options as older supportive?care drugs gradually encounter generic and biosimilar erosion. US and European oncology guidelines strongly influence uptake for such therapies, making clinical data and reimbursement decisions key for revenue trajectories.

Beyond established brands, Amgen’s pipeline is increasingly important for future revenue. The company has been investing in obesity, inflammatory diseases and oncology, where potential blockbusters could offset losses from products facing patent expiry. In the US, where pricing scrutiny is rising, Amgen is also working on value?based contracts and real?world evidence strategies to support reimbursement negotiations. This blend of legacy cash?generators and higher?risk late?stage candidates creates a portfolio where US investors frequently track clinical and regulatory milestones as catalysts for the stock.

Industry trends and competitive position

Amgen operates in a biopharmaceutical industry that is being reshaped by the rise of biologics, biosimilars and targeted therapies, especially in the United States, which remains the world’s largest drug market. Major competitors include other large biotech and pharma groups focusing on immunology, oncology and cardiovascular disease, many of which are investing heavily in similar pathways. Intensifying competition can put pressure on pricing and market share, particularly when multiple drugs target the same indications or mechanism of action.

At the same time, the increasing acceptance of biosimilars by US physicians, payers and patients has opened a parallel revenue opportunity. Amgen is both a producer and a competitor in this space, as some of its older biologics face biosimilar rivals while its own biosimilar products challenge originator brands from other companies. This dual role requires careful commercial strategy and portfolio management. The company’s long?standing manufacturing capabilities and regulatory experience in biologics may provide advantages in scaling biosimilar launches and navigating complex approval pathways in major markets.

Another major trend is the pivot toward obesity and metabolic disease treatments. Multiple global drug makers are racing to develop incretin?based therapies that target GLP?1 or related pathways, while companies like Amgen work on differentiated mechanisms such as multi?receptor agonists or antibodies that affect appetite and energy balance. Investor attention has increasingly shifted to how established biopharma groups position themselves in this fast?growing segment, with pipeline news, trial readouts and partnership announcements acting as key share?price catalysts across the sector.

Why Amgen matters for US investors

For US investors, Amgen is a significant component of the domestic biotech and pharmaceutical landscape, often included in major US equity indices and healthcare sector benchmarks. The company offers exposure to high?margin biologic drugs and late?stage clinical assets in areas that tend to be less cyclical than other industries. Demand for treatments targeting chronic conditions such as cardiovascular disease, osteoporosis and cancer is driven by demographic trends and medical need rather than short?term economic cycles, making the stock a frequent focus in health?care themed portfolios.

Amgen’s large presence on Nasdaq and deep trading liquidity make the shares accessible to both institutional and retail investors in the United States. The company has historically returned cash through dividends and share repurchases, financed by substantial operating cash flows, though the exact level of future distributions depends on pipeline investment and acquisition activity. For investors evaluating the broader US drug sector, Amgen’s results are often read as an indicator of demand trends, pricing conditions and payer behavior in key therapeutic areas.

Because the firm is headquartered in California and generates a significant portion of revenue in the US, developments in American healthcare policy are particularly relevant. Changes in Medicare reimbursement, implementation of drug price negotiation frameworks and shifts in coverage requirements for biologics and biosimilars can influence Amgen’s earnings outlook. Investors in the US closely monitor management commentary on these topics during earnings calls and regulatory disclosures, as policy changes may alter the risk?reward profile for the sector as a whole.

What type of investor might consider Amgen – and who should be cautious?

Amgen may appeal to investors looking for exposure to large?cap biotechnology with an established portfolio of marketed products and a visible late?stage pipeline. Compared with early?stage biotech firms that rely heavily on a few experimental assets, Amgen’s diversified revenue base can dampen the impact of setbacks in any single trial. This diversity, together with the company’s global commercial reach, may be attractive to investors who want biotech exposure but prefer businesses that already generate significant cash flows and operate at scale.

However, the stock may be less suitable for investors who are uncomfortable with clinical and regulatory risk. Even for large biopharma groups, late?stage trials sometimes fail to meet endpoints, and regulators may request additional data or impose label restrictions. Moreover, patent expiries and biosimilar competition can weigh on sales of mature products. Investors focused on highly predictable cash flows might view these sector?specific uncertainties as a drawback, especially when compared with industries like utilities or consumer staples.

Short?term oriented investors should also note that share prices of major biotech companies can react sharply to individual data releases, advisory committee votes or regulatory announcements. While Amgen’s scale and diversification can soften the impact of single events, the market often reprices expectations rapidly when new information emerges. This dynamic means that, even for a company of Amgen’s size, volatility around clinical catalysts and policy developments remains an inherent part of the investment profile.

Conclusion

Amgen remains a central player in global biotechnology, combining an established portfolio of biologics with efforts to build out newer franchises in areas such as oncology and metabolic disease. For US investors, the stock offers exposure to structural healthcare demand but also to the specific risks of drug development, patent cycles and reimbursement changes. The company’s large scale, manufacturing expertise and history of acquisitions provide tools to adapt its portfolio over time, yet future performance will continue to depend on how successfully Amgen advances its pipeline and navigates competition and policy shifts in its core US market.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.